JPRN-UMIN000012513招募中未知
The improvement effect of liver dysfanction and inhibitory effect of fibrosis marker by sitagliptin or repaglinide treatment for fatty liver(liver dysfunction) patients with type2 diabetes mellitus. - The improvement effect of liver dysfanction and inhibitory effect of fibrosis marker by sitagliptin or repaglinide treatment for fatty liver(liver dysfunction) patients with type2 diabetes mellitus.
Osaka Medical College Hospital0 个研究点目标入组 50 人开始时间: 2014年12月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients who have renal dysfunction 2) Patients whose medicine or its dosage changed during the study duration if antihypertensive drug, antilipidemial drug or medicine which effects on other liver functions is used. 3) Patients who are considered inappropriate as a target patient by a physician-in-charge
研究者
相似试验
已完成
Unknown
Evaluation of the improving effects on liver function, status of fatigue, mood, and sleep after ingestion of the supplementHealthy adultJPRN-UMIN000044415EP Mediate Co., Ltd.44
已完成
不适用
Examination of liver function improvement effect by administering a Ipragliflozin.DiabeticJPRN-UMIN000016198agasaki University Hospital100
已完成
不适用
Improvement effect of fatty liver and influence of periodontitis by Amazake intakeFatty liverJPRN-UMIN000030597Saga University, Department of Organ System Interactions and Information, Faculty of Medicine10
已完成
不适用
remifentanil requirements during liver transplantatioKCT0002870Samsung Medical Center40
已完成
不适用
Evaluation for efficacy of liver function by ingestion of supplement containing plant derived extractiveHealthy subjectsJPRN-UMIN000027495TTC Co., Ltd.40